These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2487557)

  • 1. Recent trends in allogeneic bone marrow transplantation.
    Gluckman E
    Clin Transpl; 1989; ():123-8. PubMed ID: 2487557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent trends in allogeneic bone marrow transplantation.
    Gluckman E
    Cancer Detect Prev; 1990; 14(6):675-8. PubMed ID: 2257566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of allogeneic bone marrow transplantation: a report from the International Bone Marrow Transplant Registry.
    Bortin MM; Gale RP
    Clin Transpl; 1986; ():17-28. PubMed ID: 3154398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of allogeneic bone marrow transplantation.
    Horowitz MM; Bortin MM
    Clin Transpl; 1990; ():41-52. PubMed ID: 2103163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia.
    Drobyski WR; Pelz C; Kabler-Babbitt C; Hessner M; Baxter-Lowe LA; Keever-Taylor CA
    Biol Blood Marrow Transplant; 1998; 4(1):3-12. PubMed ID: 9701386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia.
    Kodera Y; Morishima Y; Kato S; Akiyama Y; Sao H; Matsuyama T; Kawa K; Sakamaki H; Nakagawa S; Hirabayashi N; Dohi H; Okamoto S; Hiraoka A; Gondo H; Tsuchida M; O H; Harada M; Asano S; Juji T; Sasazuki T; Takaku F
    Bone Marrow Transplant; 1999 Nov; 24(9):995-1003. PubMed ID: 10556959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: a report of the BMT Working Party.
    Bacigalupo A; Hows J; Gordon-Smith EC; Gluckman E; Van Lint MT; Congiu M; James DC; Barrett AJ; Gmur J; De Planque MM
    Bone Marrow Transplant; 1988 Nov; 3(6):531-5. PubMed ID: 3063321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of allogeneic bone marrow transplantation in leukemia: a report from the International Bone Marrow Transplant Registry.
    Bortin MM; Gale RP
    Clin Transpl; 1987; ():127-40. PubMed ID: 3154378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-host disease after marrow transplantation.
    Storb R
    Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors.
    Bishop MR; Henslee-Downey PJ; Anderson JR; Romond EH; Marciniak E; Yankey R; Reeves M; Thompson JS
    Bone Marrow Transplant; 1996 Oct; 18(4):747-53. PubMed ID: 8899190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.
    Farag SS; Bacigalupo A; Eapen M; Hurley C; Dupont B; Caligiuri MA; Boudreau C; Nelson G; Oudshoorn M; van Rood J; Velardi A; Maiers M; Setterholm M; Confer D; Posch PE; Anasetti C; Kamani N; Miller JS; Weisdorf D; Davies SM;
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):876-84. PubMed ID: 16864058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Allogeneic bone marrow transplantation in children from related donors other than HLA-identical siblings].
    Morimoto T; Hattori K; Yabe H; Yabe M; Hinohara T; Shimizu T; Matsumoto M; Hagihara M; Tsuji K; Kato S
    Rinsho Ketsueki; 1998 Sep; 39(9):631-9. PubMed ID: 9796395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
    Carreras E; Tomás JF; Sanz G; Iriondo A; Boqué C; López J; Cabrera R; Sureda A; de Soria VG; Sierra J; Sanz MA; Torres A
    Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.